A recent presentation of data from the CheckMate 743 study at the ESMO 2021 conference has highlighted the importance of immunotherapy as first-line treatment for patients with malignant pleural mesothelioma with nearly 1 in 4 patients showing continued benefit from nivolumab plus ipilimumab at 3 years.
The data showing this long-term benefit is of great importance for patients suffering from these aggressive tumours with overall survival 1.5 times that of chemotherapy patients after a minimum follow-up of 35.5 months.
While early results from the trial changed first-line standard-of-care treatment for patients in several countries, these latest results have suggested an association between an inflammatory gene signature and overall survival which could in future lead to the development of predictive biomarker analysis.
Check out the ESMO Congress page for more information (LBA65), or refer a patient with malignant pleural mesothelioma to access professional support.
ESMO PageRefer a Patient